Addex Therapeutics (ADXN) Free Cash Flow (2019 - 2026)

Addex Therapeutics has reported Free Cash Flow for 8 years, with the latest figure at -$978.0 billion in Q1 2026.

• Quarterly Free Cash Flow fell 46.86% year-over-year to -$978.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$254.8 billion (down 115.07% YoY) and the FY2025 annual result came in at -$2.6 million, up 57.14% from the prior year.
• Free Cash Flow declined to -$978.0 billion in Q1 2026 per ADXN's latest filing, from $723.2 billion in the prior quarter.
• Over five years, Free Cash Flow peaked at $8301.5 billion in Q4 2023 and troughed at -$6175.0 billion in Q3 2024.
• A 5-year average of -$67.4 billion and a median of -$5.2 million in 2022 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2023 and 2024: Free Cash Flow surged 260252303.35% in 2023, then plunged 98657638.52% in 2024.
• Over 5 years, Free Cash Flow stood at -$3.2 million in 2022, then soared by 260252303.35% to $8301.5 billion in 2023, then decreased by 26.45% to $6105.7 billion in 2024, then plunged by 88.16% to $723.2 billion in 2025, then slumped by 235.24% to -$978.0 billion in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$978.0 billion, $723.2 billion, and -$665.9 billion for Q1 2026, Q2 2025, and Q1 2025 respectively.